Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy

Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination

(2021) Jiali Yu et al.   NATURE MEDICINE

Loss of optineurin drives cancer immune evasion via palmitoylation-dependent IFNGR1 lysosomal sorting and degradation

(2021) Wan Du et al.   Cancer Discovery

LIMIT is an immunogenic lncRNA in cancer immunity and immunotherapy

(2021) Gaopeng Li et al.   NATURE CELL BIOLOGY

Definition, Incidence, and Challenges for Assessment of Hyperprogressive Disease During Cancer Treatment With Immune Checkpoint Inhibitors

(2021) Hyo Jung Park et al.   JAMA Network Open

MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal Melanoma

(2020) Andrea Forschner et al.   Cancers

Metastatic Renal Cell Carcinoma Presenting as a Rapidly Enlarging Endotracheal Mass Due to Hyperprogression on Anti-PD1 Immunotherapy

(2020) Steven G. Hoshal et al.   ENT-EAR NOSE & THROAT JOURNAL

Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy

(2020) Jing Li et al.   JOURNAL OF CLINICAL INVESTIGATION

Loss of ELF5–FBXW7 stabilizes IFNGR1 to promote the growth and metastasis of triple-negative breast cancer through interferon-γ signalling

(2020) Snahlata Singh et al.   NATURE CELL BIOLOGY

Immunotherapy discontinuation — how, and when? Data from melanoma as a paradigm

(2020) Caroline Robert et al.   Nature Reviews Clinical Oncology

Hyperprogressive disease rarely occurs during checkpoint inhibitor treatment for advanced melanoma

(2020) M. Schuiveling et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance

(2020) Catherine L. Tan et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Hyper-Progressive Disease: The Potential Role and Consequences of T-Regulatory Cells Foiling Anti-PD-1 Cancer Immunotherapy

(2020) Christopher Tay et al.   Cancers

Novel clinical and radiomic predictors of rapid disease progression phenotypes among lung cancer patients treated with immunotherapy: An early report

(2019) Ilke Tunali et al.   LUNG CANCER

BET Inhibition Modifies Melanoma Infiltrating T Cells and Enhances Response to PD-L1 Blockade

(2019) Neda Nikbakht et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer

(2019) C G Kim et al.   ANNALS OF ONCOLOGY

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

(2019) Tony S K Mok et al.   LANCET

CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy

(2019) Weimin Wang et al.   NATURE

Hyperprogression after nivolumab for melanoma: A case report

(2019) Mesut Yilmaz et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Hyperprogression after immunotherapy in patients with malignant tumors of digestive system

(2019) Zhi Ji et al.   BMC CANCER

Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor

(2019) Youjin Kim et al.   Journal of Thoracic Oncology

Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion

(2019) Anna M. Paczulla et al.   NATURE

Clonal replacement of tumor-specific T cells following PD-1 blockade

(2019) Kathryn E. Yost et al.   NATURE MEDICINE

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

(2019) Yohann Loriot et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hyperprogression after first dose of immunotherapy in a patient with radioresistant metastasis from nonsmall cell lung cancer

(2019) Joaquim Bosch-Barrera et al.   ANTI-CANCER DRUGS

Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade

(2019) Joseph L. Benci et al.   CELL

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

(2019) Matthew D. Hellmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Capturing Hyperprogressive disease with immune checkpoint inhibitors using RECIST 1.1 criteria

(2019) Ignacio Matos et al.   CLINICAL CANCER RESEARCH

Hyperprogressive disease in advanced cancer patients treated with nivolumab

(2019) Roberto Petrioli et al.   ANTI-CANCER DRUGS

FDG PET Findings of Hyperprogression During Immunotherapy in a Patient With Hepatocellular Carcinoma

(2019) Jingnan Wang et al.   CLINICAL NUCLEAR MEDICINE

Characterization of Hyperprogression After Immunotherapy in a Lung Adenocarcinoma Patient With Strong Expression of Programmed Death Ligand 1

(2019) Yu Peng et al.   Journal of Thoracic Oncology

Oncogenic Signaling Pathways in The Cancer Genome Atlas

(2018) Francisco Sanchez-Vega et al.   CELL

Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression

(2018) Heng Lin et al.   JOURNAL OF CLINICAL INVESTIGATION

Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy

(2018) F. Stephen Hodi et al.   JOURNAL OF CLINICAL ONCOLOGY

Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion

(2018) Flávia Castro et al.   Frontiers in Immunology

Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

(2018) Roberto Ferrara et al.   JAMA Oncology

Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade

(2018) Giuseppe Lo Russo et al.   CLINICAL CANCER RESEARCH

Integrative clinical genomics of metastatic cancer

(2017) Dan R. Robinson et al.   NATURE

In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target

(2017) Robert T. Manguso et al.   NATURE

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy

(2016) Jianjun Gao et al.   CELL

Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade

(2016) Joseph L. Benci et al.   CELL

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

(2016) Stéphane Champiat et al.   CLINICAL CANCER RESEARCH

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

(2016) Louis Fehrenbacher et al.   LANCET

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

The Warburg Effect: How Does it Benefit Cancer Cells?

(2016) Maria V. Liberti et al.   TRENDS IN BIOCHEMICAL SCIENCES

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

(2016) Daniel Sanghoon Shin et al.   Cancer Discovery

Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer

(2016) R. F. Sweis et al.   Cancer Immunology Research

Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade

(2016) Tavi Nathanson et al.   Cancer Immunology Research

Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells

(2016) B. Homet Moreno et al.   Cancer Immunology Research

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

Integrative Clinical Genomics of Advanced Prostate Cancer

(2015) Dan Robinson et al.   CELL

TGF-β Promotes Heterogeneity and Drug Resistance in Squamous Cell Carcinoma

(2015) Naoki Oshimori et al.   CELL

Pseudoprogression and Immune-Related Response in Solid Tumors

(2015) Victoria L. Chiou et al.   JOURNAL OF CLINICAL ONCOLOGY

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

(2015) Stefani Spranger et al.   NATURE

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

(2015) E. M. Van Allen et al.   SCIENCE

NAD+ and sirtuins in aging and disease

(2014) Shin-ichiro Imai et al.   TRENDS IN CELL BIOLOGY

ARF and p53 Coordinate Tumor Suppression of an Oncogenic IFN-β-STAT1-ISG15 Signaling Axis

(2014) Jason T. Forys et al.   Cell Reports

Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials

(2013) C. Ferte et al.   CLINICAL CANCER RESEARCH

SIRT1 regulates differentiation of mesenchymal stem cells by deacetylating β-catenin

(2013) Petra Simic et al.   EMBO Molecular Medicine

Small-Molecule Inhibitors of Acetyltransferase p300 Identified by High-Throughput Screening Are Potent Anticancer Agents

(2013) H. Yang et al.   MOLECULAR CANCER THERAPEUTICS

Wnt/β-Catenin Signaling and Disease

(2012) Hans Clevers et al.   CELL

Glucose-Induced β-Catenin Acetylation Enhances Wnt Signaling in Cancer

(2012) Ana Chocarro-Calvo et al.   MOLECULAR CELL

A restricted cell population propagates glioblastoma growth after chemotherapy

(2012) Jian Chen et al.   NATURE

Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis

(2012) Dimitrios Anastasiou et al.   Nature Chemical Biology

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation

(2011) Weiwei Yang et al.   NATURE

Inhibition of Pyruvate Kinase M2 by Reactive Oxygen Species Contributes to Cellular Antioxidant Responses

(2011) D. Anastasiou et al.   SCIENCE

Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271

(2010) Alexander D. Boiko et al.   NATURE

Wnt/β-Catenin Signaling: Components, Mechanisms, and Diseases

(2009) Bryan T. MacDonald et al.   DEVELOPMENTAL CELL

Tyrosine Phosphorylation Inhibits PKM2 to Promote the Warburg Effect and Tumor Growth

(2009) T. Hitosugi et al.   Science Signaling

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect

(2008) E Lara et al.   ONCOGENE